When nausea and vomiting persist during chemotherapy, it is easy to try one or two prescribed medicines and conclude that anti-nausea drugs simply do not work for this person. But vomiting is not a single switch. The gut lining, the vomiting center and chemoreceptor trigger zone in the brain, the vestibular system, and anxiety each drive the same outcome through different pathways. That is why the sentence "it isn't working" usually contains at least four separate situations.

First, drug classes differ. The dopamine-blocking agents (such as metoclopramide) and the serotonin 5-HT3 blockers (such as ondansetron) are commonly used first, but the list of antiemetic options does not end there. NK-1 receptor antagonists (aprepitant and related drugs), corticosteroids such as dexamethasone, olanzapine, antihistamine and anticholinergic agents, and benzodiazepines for anticipatory nausea act on different receptors. When one class fails, adding or switching to a different class is generally discussed rather than simply increasing the dose of the same class. Which combination is appropriate depends on how emetogenic the chemotherapy regimen is and on the patient's other conditions and medications.

Second, the route of administration matters. If a tablet is vomited immediately after swallowing, the drug never had time to be absorbed. That is closer to "the medicine did not get in" than "the medicine did not work." Intravenous, subcutaneous, rectal, orally disintegrating, and transdermal patch forms exist precisely for this situation. Simply telling the team how many minutes passed between the dose and the vomiting can change the next prescription.

Third, the problem may be a side effect of the drug itself. Severe restlessness, an inability to sit still, or muscle stiffness after an injection may reflect akathisia or extrapyramidal effects known to occur with dopamine-blocking agents, rather than uncontrolled nausea. This is a different problem from lack of efficacy, and it should be reported rather than endured, since another class can usually be substituted. It also helps to describe dizziness precisely: a spinning sensation, light-headedness on standing, and agitated restlessness point in different directions.

Fourth, the cause may not be the chemotherapy at all. In advanced gastric cancer, gastric outlet obstruction or bowel obstruction from tumor or peritoneal disease, ascites, electrolyte abnormalities such as hypercalcemia or hyponatremia, reduced kidney function, opioid analgesics, severe constipation, infection, and less commonly brain lesions can all cause vomiting. When the cause lies here, antiemetics alone are expected to fall short, and blood tests, imaging, nasogastric decompression, stenting or other procedures, and secretion-reducing medicines may be considered alongside.

Signs that should be reported without waiting include blood or coffee-ground material in the vomit, a distended abdomen with no gas or stool passing, inability to keep down even water for more than a day, a clear drop in urine output with light-headedness on standing, fever or confusion, and severe headache or visual changes.

Before the next ward round or clinic visit, write down five things: when the vomiting started and how many times a day; the last meal and the last passage of stool or gas; which medicine was given, at what time, in what form, and how many minutes passed before vomiting; the exact wording of any dizziness or restlessness after a dose; and urine frequency plus weight change. With those five lines, "the medicine isn't working" becomes a specific question about which pathway is blocked. Useful questions in the room include which class the current drug belongs to, whether another class can be added, what non-oral routes are available, whether tests are needed to look for another cause, and whether a palliative care or supportive care team can be involved for symptom control.

This article is general health information and does not replace individual diagnosis or treatment. Drug choices, doses, and timing of tests depend on each patient's condition and treatment plan, so please discuss any decisions with your medical team.